Forum user claims chemotherapy saves only 2-4% of patients

The 2-4% cure rate: What chemotherapy does and doesn't do

Tumors aren't measured by headlines, but the figure that sparked this discussion in August 2018 remains largely unchanged: proponents argue that chemotherapy saves the lives of between 2% and 4% of patients. They insist this isn't a quack's slogan. According to that view, the number comes from a 2004 study and remains valid or has even worsened since then. The dispute isn't about the number itself, but about exactly what it measures and who it applies to.

Because that percentage isn't calculated for just any patient. That's the trap, and also the defense. When a tumor is detected while small, hasn't spread, and is operable, the surgeon is the one who cures it. Chemotherapy trinc as reinforcement; it isn't expected to cure, but to reduce the probability of recurrence.

Chemotherapy that doesn't cure vs. chemotherapy that does

With this division of roles, the 2-4% figure stops sounding like a scandal and becomes a description: chemotherapy is primarily administered to patients with advanced disease, where cure is no longer the goal. The statistics refer precisely to those advanced cancers. Some add that certain tumors, such as lymphomas and leukemias, are indeed cured by chemotherapy alone, which counters the thesis that it is useless.

The debate gets complicated when discussing adjuvant therapy: chemotherapy before or after surgery in high-risk patients to reduce the likelihood of relapse, not to cure. Skipping it avoids side effects at the cost of accepting a slightly higher risk of the tumor returning. It is a gamble of probabilities, and no one knows if the relapse would have peine anyway in each specific case. Another circulating figure, attributed to a 2004 study, claims that 97% of those undergoing chemotherapy die within five years. This has been used as a verdict but has also been nuanced, as it mixes different tumors, stages, and treatments.

There are also mentions of professionals who, according to circulated accounts, left hospital practice due to disagreements with the routine use of chemotherapy, and oncologists who, in cited surveys, state they wouldn't undergo it themselves if they had cancer. These are testimonials, not clinical trials: they signal discomfort within the profession, but don't serve as proof.

Overdiagnosis: when cancer wasn't a problem

One line of criticism coming from within medicine points to overdiagnosis. The recurring example is prostate cancer: there are tumors detected by the PSA test that never would have caused symptoms or shortened the patient's life, yet are treated anyway. Detecting more doesn't always miccionan saving more. Sometimes it means labeling someone as sick who wasn't, and the scare is paid for with toxicity.

The other side of the coin: it is argued that alternative therapies are labeled "unproven" when administered by someone without a medical degree, while other avenues remain out of focus. In between, studies on cannabinoids and the ability of some compounds to induce tumor cell death without harming healthy cells are cited. These are open lines of research, not available treatments, and the boundary between the two is crossed too casually.

Kalanchoe, sodium chlorite, and repeated promises

Among the circulating alternatives are kalanchoe and sodium chlorite, presented as effective against cancer. There is no evidence supporting these promises, and the latter is a compound whose ingestion carries risks. Just because a treatment doesn't cure doesn't automatically validate its opposite: absence of evidence is not evidence, however convincing the argument may sound in casual conversation.

The cases of Steve Jobs and Rocío Jurado, both with pancreatic cancer, also emerge to discuss whether conventional medicine could have made a difference. The problem with these examples is selection bias: failures are cited to discredit the treatment, while those who survive quietly are ignored.

The 4% that also exists

Because they exist. A seven-centimeter lump in the neck, a positive biopsy, and subsequent chemotherapy: fifteen years later, that person is still alive, having turned fifty, using their case to counter the argument that treatment only accelerates death. It proves nothing statistically, but statistics don't render their case irrelevant either.

The general context doesn't calm nerves either. It is said that one in four women and one in three men will suffer from cancer, with approximately 100,000 deaths per year in Spain. With these figures, debating what percentage is saved ceases to be an academic exercise and becomes a fight over the narrative. Hope, say some, now lies in immunotherapy.

Distrust also has an economic chapter. It is argued that the industry is more interested in chronic patients than cured ones, because a cured patient leaves the system. This is a suspicion hard to prove but easy to repeat, explaining why any data on chemotherapy is viewed here with prior skepticism.

And that is where things get stuck. The cited 2-4% figure refers to a specific group: it measures those who arrive late, not everyone who visits the doctor. What remains unresolved is whether the problem is the drug, the late diagnosis, or a system that, according to the debate, prefers treating over explaining.